Endothelial dysfunction in the streptozotocin-induced diabetic apoE-deficient mouse

British Journal of Pharmacology

Volumn 146, Issue 8, 2005, Pages 1110-1118

  Ding, Hong ^a   Hashem, Michael ^a   Wiehler, William B ^b   Lau, Winnie ^a   Martin, Jacqueline ^a   Reid, Julianne ^a   Triggle, Chris ^a  

^a RMIT UNIVERSITY   (Australia)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Apamin; apoE deficient; Atherosclerosis; Connexins; Diabetes; EDHF; Endothelium; eNOS; SK Ca channels; Streptozotocin; TRAM 34

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ACETYLCHOLINE; APAMIN; APOLIPOPROTEIN E; CITRIC ACID; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GAP JUNCTION PROTEIN; GUANYLATE CYCLASE INHIBITOR; INDOMETACIN; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; MESENTERIC ARTERY; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA; APOLIPOPROTEINS E; BIOLOGICAL FACTORS; CONNEXINS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; MESENTERIC ARTERIES; MICE; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; STREPTOZOCIN; VASODILATION; VASODILATOR AGENTS;

EID: 28944444040     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706417     Document Type: Article

References (63)

1. ALP, N.J. & CHANNON, K.M. (2004). Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler. Thromb. Vasc. Biol., 24, 413-420.
2. ANDERSON, T.J. (1999). Assessment and treatment of endothelial dysfunction in humans. J. Am. Coll. Cardiol., 34, 631-638.
3. ANDREWS, K.L., PANNIRSELVAM, M., ANDERSON, T.J., JENKINS, A.J., TRIGGLE, C.R. & HILL, M.A. (2005). The vascular endothelium in diabetes: a practical target for drug treatment? Expert Opin. Ther. Targets, 9, 101-117.
4. BURNHAM, M.P., BYCHKOV, R., FELETOU, M., RICHARDS, G.R., VANHOUTTE, P.M., WESTON, A.H. & EDWARDS, G. (2002). Characterization of an apamin-sensitive small-conductance Ca(2+)-activated K(+) channel in porcine coronary artery endothelium: relevance to EDHF. Br. J. Pharmacol., 135, 1133-1143.
5. BUSSE, R., EDWARDS, G., FELETOU, M., FLEMING, I., VANHOUTTE, P.M. & WESTON, A.H. (2002). EDHF: bringing the concepts together. Trends Pharmacol. Sci., 23, 374-380.
6. CHATAIGNEAU, T., FELETOU, M., HUANG, P.L., FISHMAN, M.C., DUHAULT, J. & VANHOUTTE, P.M. (1999). Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br. J. Pharmacol., 126, 219-226.
7. COLEMAN, D.L. (1982). Diabetes-obesity syndromes in mice. Diabetes, 31 (Suppl 1), 1-6.
8. + channels provide different facets of endothelium-dependent hyperpolarization in rat mesenteric artery. J. Physiol., 553, 183-189.
9. Ca activity and reduced EDHF responses in the rat isolated mesenteric artery. Br. J. Pharmacol., 142, 43-50.
10. CRAUWELS, H.M., VAN HOVE, C.E., HOLVOET, P., HERMAN, A.G. & BULT, H. (2003). Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. Effect of human apolipoprotein AI. Cardiovasc. Res., 59, 189-199.
11. DE VRIESE, A.S., VAN DE VOORDE, J., BLOM, H.J., VANHOUTTE, P.M., VERBEKE, M. & LAMEIRE, N.H. (2000). The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin- induced diabetic rats is restored by 5-methyltetrahydrofolate. Diabetologia, 43, 1116-1125.
12. DE WIT, C., ROOS, F., BOLZ, S.S., KIRCHHOFF, S., KRUGER, O., WILLECKE, K. & POHL, U. (2000). Impaired conduction of vasodilation along arterioles in connexin40-deficient mice. Circ. Res., 86, 649-655.
13. DING, H., KUBES, P. & TRIGGLE, C.R. (2000). Potassium- and acetylcholine-induced vasorelaxation in mice lacking endothelial nitric oxide synthase. Br. J. Pharmacol., 129, 1194-1200.
14. DING, H. & TRIGGLE, C.R. (2005). Endothelial cell dysfunction and the vascular complications associated with type II diabetes: assessing the health of the endothelium. Vasc. Health Risk Manage., 1, 55-71.
15. DORA, K.A., SANDOW, S.L., GALLAGHER, N.T., TAKANO, H., RUMMERY, N.M., HILL, C.E. & GARLAND, C.J. (2003). Myoendothelial gap junctions may provide the pathway for EDHF in mouse mesenteric artery. J. Vasc. Res., 40, 480-490.
16. DUNCAN, L.E. (1963). Evolution of the Atherosclerotic Plaque. ed. Jones, R.J.. Chicago: University of Chicago Press.
17. +-channels suppresses EDHF-mediated vasodilation. Br. J. Pharmacol., 138, 594-601.
18. FELETOU, M. & VANHOUTTE, P.M. (2004). EDHF: new therapeutic targets? Pharmacol. Res., 49, 565-580.
19. FUKAO, M., HATTORI, Y., KANNO, M., SAKUMA, I. & KITABATAKE, A. (1997). Alterations in endothelium-dependent hyperpolarization and relaxation in mesenteric arteries from streptozotocin-induced diabetic rats. Br. J. Pharmacol., 121, 1383-1391.
20. FUNADA, J., SEKIYA, M., HAMADA, M. & HIWADA, K. (2002). Postprandial elevation of remnant lipoprotein leads to endothelial dysfunction. Circ. J., 66, 127-132.
21. GARLAND, C.J. & PLANE, F. (1996). Endothelium-Derived Hyperpolarizing Factor. New York: Harwood Academic Publishers, pp. 173-179.
22. GRUNDY, S.M., BENJAMIN, I.J., BURKE, G.L., CHAIT, A., ECKEL, R.H., HOWARD, B.V., MITCH, W., SMITH JR, S.C. & SOWERS, J.R. (1999). Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation, 100, 1134-1146.
23. GRUNDY, S.M., HOWARD, B., SMITH JR, S., ECKEL, R., REDBERG, R. & BONOW, R.O. (2002). Prevention conference VI: Diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation, 105, 2231-2239.
24. HAFFNER, S.M., LEHTO, S., RONNEMAA, T., PYORALA, K. & LAAKSO, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 339, 229-234.
25. HARADA, K., SHIMANO, H., ISHIBASHI, S. & YAMADA, N. (1996). Transgenic mouse and gene therapy. Diabetes, 45 (Suppl 3), S129-S132.
26. HINK, U., LI, H., MOLLNAU, H., OELZE, M., MATHEIS, E., HARTMANN, M., SKATCHKOV, M., THAISS, F., STAHL, R.A., WARNHOLTZ, A., MEINERTZ, T., GRIENDLING, K., HARRISON, D.G., FORSTERMANN, U. & MUNZEL, T. (2001). Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res., 88, E14-E22.
27. HUANG, P.L., HUANG, Z., MASHIMO, H., BLOCH, K.D., MOSKOWITZ, M.A., BEVAN, J.A. & FISHMAN, M.C. (1995). Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature, 377, 239-242.
28. KAMATA, K., NAKAJIMA, M. & SUGIURA, M. (1999). Effects of superoxide dismutase on the acetylcholine-induced relaxation response in cholesterol-fed and streptozotocin-induced diabetic mice. J. Smooth Muscle Res., 35, 33-46.
29. KAWANO, H., MOTOYAMA, T., HIRASHIMA, O., HIRAI, N., MIYAO, Y., SAKAMOTO, T., KUGIYAMA, K., OGAWA, H. & YASUE, H. (1999). Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J. Am. Coll. Cardiol., 34, 146-154.
30. KAWASHIMA, S. & YOKOYAMA, M. (2004). Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 24, 998-1005.
31. KOBAYASHI, T. & KAMATA, K. (2001). Effect of chronic insulin treatment on NO production and endothelium-dependent relaxation in aortae from established STZ-induced diabetic rats. Atherosclerosis, 155, 313-320.
32. LAAKSO, M. (1999). Hyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes. Prim. Care, 26, 829-839.
33. LIBBY, P. & PLUTZKY, J. (2002). Diabetic macrovascular disease: the glucose paradox? Circulation, 106, 2760-2763.
34. LIVAK, K.J. & SCHMITTGEN, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25, 402-408.
35. MATHER, S., DORA, K.A., SANDOW, S.L., WINTER, P. & GARLAND, C.J. (2005). Rapid endothelial cell-selective loading of connexin 40 antibody blocks endothelium-derived hyperpolarizing factor dilation in rat small mesenteric arteries. Circ. Res., 97, 399-407.
36. MATSUMOTO, T., KOBAYASHI, T. & KAMATA, K. (2003). Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am. J. Physiol. Heart Circ. Physiol., 285, H283-H291.
37. MATSUMOTO, T., WAKABAYASHI, K., KOBAYASHI, T. & KAMATA, K. (2004). Diabetes-related changes in cAMP-dependent protein kinase activity and decrease in relaxation response in rat mesenteric artery. Am. J. Physiol. Heart Circ. Physiol., 287, H1064-H1071.
38. MCGUIRE, J.J., DING, H. & TRIGGLE, C.R. (2001). Endothelium-derived relaxing factors: a focus on endothelium-derived hyperpolarizing factor(s). Can. J. Physiol. Pharmacol., 79, 443-470.
39. MCGUIRE, J.J., HOLLENBERG, M. & TRIGGLE, C.R. (2004). Hyperpolarization of vascular smooth muscle by the activation of endothelial proteinase-activated receptor 2 in murine small mesenteric arteries. Can. J. Physiol. Pharmacol., 82, 1103-1112.
40. MEIR, K.S. & LEITERSDORF, E. (2004). Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioseler. Thromb. Vasc. Biol., 24, 1006-1014.
41. MULVANY, M.J. & HALPERN, W. (1977). Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res., 41, 19-26.
42. NAWATE, S., FUKAO, M., SAKUMA, I., SOMA, T., NAGAI, K., TAKIKAWA, O., MIWA, S. & KITABATAKE, A. (2005). Reciprocal changes in endothelium-derived hyperpolarizing factor- and nitric oxide-system in the mesenteric artery of adult female rats following ovariectomy. Br. J. Pharmacol., 144, 178-189.
43. NISHIKAWA, T., EDELSTEIN, D. & BROWNLEE, M. (2000). The missing link: a single unifying mechanism for diabetic complications. Kidney Int., 77 (Suppl.), S26-S30.
44. OZAKI, M., KAWASHIMA, S., YAMASHITA, T., HIRASE, T., NAMIKI, M., INOUE, N., HIRATA, K., YASUI, H., SAKURAI, H., YOSHIDA, Y., MASADA, M. & YOKOYAMA, M. (2002). Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J. Clin. Invest., 110, 331-340.
45. PANNIRSELVAM, M., SIMON, V., VERMA, S., ANDERSON, T.J. & TRIGGLE, C.R. (2003). Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. Br. J. Pharmacol., 140, 701-706.
46. PANNIRSELVAM, M., VERMA, S., ANDERSON, T.J. & TRIGGLE, C.R. (2002). Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db-/-) mice: role of decreased tetrahydrobiopterin bioavailability. Br. J. Pharmacol., 136, 255-263.
47. PANNIRSELVAM, M., WIEHLER, W.B., ANDERSON, T.J. & TRIGGLE, C.R. (2005). Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products. Br. J. Pharmacol., 144, 953-966.
48. PIEPER, G.M. (1999). Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia, 142, 204-213.
49. ROSS, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801-809.
50. ROSS, R. & GLOMSET, J.A. (1973). Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science, 190, 1332-1339.
51. RUMMERY, N.M. & HILL, C.E. (2004). Vascular gap junctions and implications for hypertension. Clin. Exp. Pharmacol. Physiol., 31, 659-667.
52. SANDOW, S.L. (2004). Factors, fiction and endothelium-derived hyperpolarizing factor. Clin. Exp. Pharmacol. Physiol., 31, 563-570.
53. STADLER, R.W., IBRAHIM, S.F. & LEES, R.S. (1997). Peripheral vasoactivity in familial hypercholesterolemic subjects treated with heparin-induced extracorporeal LDL precipitation (HELP). Atherosclerosis, 128, 241-249.
54. TAKANO, H., DORA, K.A., SPITALER, M.M. & GARLAND, C.J. (2004). Spreading dilatation in rat mesenteric arteries associated with calcium-independent endothelial cell hyperpolarization. J. Physiol., 556, 887-903.
55. + (SK3) channels modulates arterial tone and blood pressure. Circ. Res., 93, 124-131.
56. TRIGGLE, C.R., HOLLENBERG, M., ANDERSON, T.J., DING, H., JIANG, Y., CERONI, L., WIEHLER, W.B., NG, E.S., ELLIS, A., ANDREWS, K., MCGUIRE, J.J. & PANNIRSELVAM, M. (2003). The endothelium in health and disease - a target for therapeutic intervention. J. Smooth Muscle Res., 39, 249-267.
57. VANHOUTTE, P.M. (2004). Endothelium-dependent hyperpolarizations: the history. Pharmacol. Res., 49, 503-508.
58. VERMA, S. & ANDERSON, T.J. (2002). Fundamentals of endothelial function for the clinical cardiologist. Circulation, 105, 546-549.
59. VITA, J.A., TREASURE, C.B., NABEL, E.G., MCLENACHAN, J.M., FISH, R.D., YEUNG, A.C., VEKSHTEIN, V.I., SELWYN, A.P. & GANZ, P. (1990). Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation, 81, 491-497.
60. WALDRON, G.J., DING, H., LOVREN, F., KUBES, P. & TRIGGLE, C.R. (1999). Acetylcholine-induced relaxation of peripheral arteries isolated from mice lacking endothelial nitric oxide synthase. Br. J. Pharmacol., 128, 653-658.
61. WIGG, S.J., TARE, M., TONTA, M.A., O'BRIEN, R.C., MEREDITH, I.T. & PARKINGTON, H.C. (2001). Comparison of effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery. Am. J. Physiol. Heart Circ. Physiol., 281, H232-H240.
62. + channel, IKCa1: a potential immunosuppressant. Proc. Natl. Acad. Sci. U.S.A., 97, 8151-8156.
63. YAMAMOTO, K., SHIMANO, H., SHIMADA, M., KAWAMURA, M., GOTODA, T., HARADA, K., OHSUGA, J., YAZAKI, Y. & YAMADA, N. (1995). Overexpression of apolipoprotein E prevents development of diabetic hyperlipidemia in transgenic mice. Diabetes, 44, 580-585.